Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Mitoxantrone treatment of multiple sclerosis: Safety considerations
Bruce A. Cohen
*
, Daniel D. Mikol
*
Corresponding author for this work
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
68
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Mitoxantrone treatment of multiple sclerosis: Safety considerations'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Mitoxantrone
100%
Multiple Sclerosis
57%
Adverse Event
42%
Urinary Tract Infection
28%
Cardiotoxicity
28%
Razoxane
28%
Heart Failure
14%
Neoplasm
14%
Nausea
14%
Hypertransaminasemia
14%
Anthracycline
14%
Tolerability
14%
Leukopenia
14%
Clinical Study
14%
Infection
14%
Leukemia
14%
Amenorrhea
14%
Alopecia
14%
Cardiomyopathy
14%
Phase IV
14%
Side Effect
14%
Ethinylestradiol Plus Megestrol Acetate
14%
INIS
patients
57%
doses
57%
monitoring
42%
safety
42%
toxicity
42%
risks
28%
laboratories
14%
administration
14%
liver
14%
reduction
14%
leukemia
14%
side effects
14%
neoplasms
14%
heart failure
14%
urine
14%
enzymes
14%
nausea
14%
urinary tract
14%
amenorrhea
14%
leukopenia
14%